Full-Time
Territory Manager
Inspire Medical Systems
1,001-5,000 employees
FDA-approved neurostimulation device for OSA
Compensation Overview
$80k/yr
Harrisburg, PA, USA
In Person
Must travel within the territory, including overnights as needed.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Inspire Medical Systems
See people who can refer or advise you
- Bachelor’s degree with 2 years minimum sales experience in Medical Device or Pharmaceutical industry. In lieu of a degree, 5 years minimum sales experience in Medical Device or Pharmaceutical industry or 3 years previous experience at Inspire Medical Systems working directly with our therapy in a clinical setting.
- Strong computer skills with MS Office including PowerPoint and Excel.
- Ability to manage simultaneous priorities, changing deadlines.
- Ability to travel (including overnights as needed) within territory.
- Lead commercialization activities introducing Obstructive Sleep Apnea therapy to assigned sales territory.
- Achieve sales plan and therapy awareness milestones. Assess new potential accounts within assigned sales territory.
- Drives implant growth to achieve sales plan through prompt account activation and efficient patient throughput.
- Orchestrates commercial site assessment, selection, and development.
- Achieves and exceeds assigned sales quota.
- Ensures commercial centers follow patient selection guidelines, implant techniques and effective therapy method.
- Facilitates local payer education and development process.
- Works closely with marketing and sales operations teams to refine and enhance both organic and direct-to-patient outreach programs.
- A solid understanding of Obstructive Sleep Apnea technology as well as device implantation and follow-up procedures.
- Experience with assisting in the implantation and follow up of implantable devices.
- Experience in market development and building referral programs within the medical industry.
- Product launch and account experience.
Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Golden Valley, Minnesota
Founded
2007
Get referred to Inspire Medical Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- CMS proposed 2027 facility reimbursement increases for Inspire V on August 2026 filings.
- Management raised 2026 revenue guidance to $835 million-$875 million after Q2 beat.
- Project Horizon and Michael H. Carrel's board appointment sharpen access and execution focus.
What critics are saying
- Coding confusion cut Q2 2026 revenue by $40 million and pressured 2026 guidance.
- WISeR prior authorization and CPT 64582 modifier friction can delay adoption through 2026.
- If reimbursement stays muddled until 2028, Inspire loses physician economics and growth leadership.
What makes Inspire Medical Systems unique
- Only FDA-approved implanted neurostimulation therapy for moderate-to-severe OSA with CPAP failure.
- 3 Tesla MRI compatibility expanded usability for implanted sleep-apnea patients in February 2026.
- Direct U.S. sales and in-house reimbursement navigation create a specialized commercial moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Tuition Reimbursement
Employee Assistance program
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.
Inspire Medical Systems shares have risen 28.1% in the past month following a second-quarter earnings beat and raised 2026 guidance. The company reported adjusted earnings of 14 cents per share, surpassing consensus estimates for a 22-cent loss, whilst revenues of $200.6 million exceeded expectations despite declining 7.6% year over year. Management increased its 2026 revenue outlook to $835–875 million and raised adjusted earnings guidance to $1.05–$1.45 per share. The Zacks consensus estimate for 2026 earnings increased 34.7% over the past four weeks. However, coding challenges and prior authorisation programmes reduced second-quarter revenues by approximately $40 million. Management expects a full-year impact of $120–130 million and forecasts an 8–10% revenue decline in the third quarter.
Inspire Medical Systems appointed AtriCure CEO Michael H. Carrel to its Board as director Casey M. Tansey plans to retire. The company reported quarterly revenue of $200.58 million and earnings of $0.14 per share, exceeding analyst expectations despite a year-on-year decline. Inspire raised its full-year outlook and launched Project Horizon, targeting $30 million in annualised investment capacity for patient access and education. The initiative comes alongside proposed reimbursement increases for its Inspire 5 procedure in 2027. The company's revenue narrative projects $987.4 million revenue and $67.1 million earnings by 2029. Investors are weighing the impact of Project Horizon against ongoing reimbursement and coding volatility affecting the firm's implant-based approach to obstructive sleep apnea treatment.
Inspire Medical Systems reported second-quarter revenue of $200.6 million, beating analyst estimates by 3% despite a 7.6% year-on-year decline. The medical technology company, which develops implantable devices for obstructive sleep apnea treatment, posted adjusted earnings per share of $0.14, significantly exceeding the consensus estimate of -$0.25. The company raised its full-year revenue guidance to $855 million at the midpoint, 1.4% above analyst expectations. Management also increased full-year adjusted EPS guidance to $1.25, a 25% rise. Adjusted EBITDA reached $38.9 million with a 19.4% margin, beating estimates by 40.5%. Following the results, Inspire Medical Systems' stock jumped 13.6%. CEO Tim Herbert attributed the performance to increased discipline whilst navigating evolving coding and reimbursement challenges.
Inspire Medical Systems will report Q2 earnings on Monday after the bell. The medical technology company is expected to see revenue decline 10.3% year on year, a reversal from the 10.8% increase recorded in the same quarter last year. Last quarter, Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year on year, beating analysts' expectations. However, the company's full-year revenue and EPS guidance missed estimates significantly. Analysts have generally reconfirmed their estimates over the last 30 days. Inspire Medical Systems shares are up 3.6% over the past month, trading at $51.21 against an average analyst price target of $51.43. Peers Bausch + Lomb and Baxter recently beat Q2 revenue expectations, with shares rising 2.7% and 5.7% respectively following their results.